ocifisertib

N/A

Report date: 2024/02/21 17:17:43
NMEFirst In Class

Base Information

Drug Nameocifisertib
Drug Alias NameCFI-400945CFI 400945 fumarate
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPolo like kinase 4 inhibitors
TargetsPolo like kinase 4
Therapy Area/IndicationsMyelodysplastic SyndromesBreast NeoplasmsLeukemia, Myelomonocytic, Chronic +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesHong Kong
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Health Network (Uhn)
China Registration ClassN/A

Develop Information

Active CompaniesTreadwell Therapeutics IncUniversity Health Network (Uhn)
Inactive CompaniesN/A
Active IndicationsMyelodysplastic SyndromesBreast NeoplasmsLeukemia, Myelomonocytic, Chronic +[4] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A